Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Receives CAP Accreditation, Coverage Eligibility from Blue Shield of California and CMS

NEW YORK (GenomeWeb) – Invitae has received accreditation for its laboratory from the College of American Pathologists as well as coverage eligibility from Blue Shield of California and the Centers for Medicare and Medicaid Services, the company said this week.

"Securing reimbursement is an important step towards realizing our mission to make genetic testing affordable and accessible for patients,” Lisa Alderson, Invitae's chief commercial officer, said in a statement.

The CAP accreditation adds to the existing CLIA certification of Invitae's laboratory. The San Francisco-based company offers a clinical assay of 216 genes associated with 85 genetic disorders, which includes 17 targeted panels that focus on hereditary cancers, cardiology, hematology, neurology, and pediatrics.

According to its website, physicians in the US can order any combination of genes, disorders, and panels at a contract price of $1,500. The majority of Invitae's tests, which use next-generation sequencing technology, have a turnaround time of less than three weeks, according to the company.

This fall, Invitae completed a $120 million Series F financing round.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.